How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/psma-positive-metastatic-castration-resistant-prostate-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PSMA-positive metastatic castration-resistant prostate cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PSMA-positive metastatic castration-resistant prostate cancer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating PSMA-positive metastatic castration-resistant prostate cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Pluvicto	Lutetium (177Lu) vipivotide tetraxetan	Aaa Usa Novartis	Radioligand Therapeutic Agent [EPC]	Prostate-specific antigen		2022-01-01
Pluvicto	Pluvicto	VA Office of Research and Development		Prostate-specific antigen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Aaa Usa Novartis · 1 drug in PSMA-positive metastatic castration-resistant prostate cancer
VA Office of Research and Development · 1 drug in PSMA-positive metastatic castration-resistant prostate cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in PSMA-positive metastatic castration-resistant prostate cancer:

Cite this brief

Drug Landscape (2026). PSMA-positive metastatic castration-resistant prostate cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed 2026-06-10.

PSMA-positive metastatic castration-resistant prostate cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing